|FOR IMMEDIATE RELEASE|
Thursday, May 25, 2000
4:00 p.m. EDT
NIAID Creates Global Network to Advance Development of HIV Vaccines
- Robert Belshe, M.D. - Saint Louis University, Missouri
- William Blattner, M.D. - University of Maryland, Baltimore
- Donald Burke, M.D. - Johns Hopkins University, Baltimore, Maryland
- Susan Buchbinder, M.D. - San Francisco Department of Health,
- Raphael Dolin, M.D. - Harvard University, Boston, Massachusetts
- Barney Graham, M.D., Ph.D. - Vanderbilt University, Nashville, Tennessee
- Michael Keefer, M.D. - University of Rochester, New York
- Julie McElrath, M.D. - Fred Hutchinson Cancer Research Center and
University of Washington, Seattle
- Mark Mulligan, M.D. - University of Alabama at Birmingham
NIAID is also convening a National HIV Vaccine Communications Steering Group
to stimulate and enhance the national dialogue concerning HIV preventive
vaccines. The Steering Group, composed of HIV vaccine advocates and
communications specialists, will work closely with the HVTN to create a
supportive environment for future vaccine studies.
Besides the HVTN, NIAID is also establishing a parallel network, the HIV
Prevention Trials Network (HPTN), which will conduct research on a broad
range of HIV prevention strategies. Domestically and internationally, the
HPTN will evaluate and test microbicides and other promising biomedical and
behavioral interventions, including vaccines to prevent transmission of HIV
from mother to infant.
NIAID is a component of the National Institutes of Health (NIH). NIAID
conducts and supports research to prevent, diagnose and treat illnesses such
as HIV disease and other sexually transmitted diseases, tuberculosis,
malaria, asthma and allergies. NIH is an agency of the U.S. Department of
Health and Human Services.
Press releases, fact sheets and other NIAID-related materials are available
on the NIAID Web site at www.niaid.nih.gov.